Objective: As women with human immunodeficiency virus (HIV) are living longer, more are entering perimenopause. Prior studies suggest that HIV-infected women are more likely to have hot flashes than nonYHIV-infected women. However, little is known regarding hot flash severity and hot flashYrelated interference with daily function, mood, and quality of life in this population.
M
enopause is associated with a number of bothersome symptoms, including hot flashes, 1<3 and prior studies suggest that these symptoms peak during perimenopause. 1, 4 Vasomotor symptoms or hot flashes are reported to be the most common symptoms associated with menopause, 5, 6 and such symptoms are both burdensome and distressing. Hot flashes are also associated with increased anxiety and depressive symptoms during early perimenopause. 5, 7, 8 A recent study among a large, racially diverse cohort of human immunodeficiency virus (HIV)Yinfected and nonYHIV-infected premenopausal, perimenopausal, and postmenopausal women showed that those experiencing persistent hot flashes were approximately 45% more likely to experience elevated depressive symptoms. 4 Collectively, menopausal symptoms negatively impact quality of life, relationships, and role performance. 9 As the life span of HIV-infected women increases, more are entering perimenopause. Prior studies suggest that HIVinfected women initiate menopause at a younger age than nonYHIV-infected women 10<13 and, consequently, may encounter hot flashes and other related symptoms earlier. The burdensome nature of hot flashes, coupled with depression and other comorbidities commonly associated with HIV, 14, 15 may further reduce quality of life in this population during perimenopause. Collectively, these symptoms may negatively impact adherence to antiretroviral therapy (ART) 16 and increase the risk of developing an acquired immune deficiency syndromeYdefining illness, 17 as prior studies have shown that those with depression have poor adherence to ART. 18, 19 Few clinical studies evaluating menopause symptoms among HIV-infected women have been conducted, 11,13,20<22 and the majority of these studies have reported on the prevalence of menopause symptoms versus degree of symptom severity or related interference. Two prior studies reported on hot flash prevalence among cohorts of premenopausal, perimenopausal, and postmenopausal HIV-infected women and found that postmenopausal HIV-infected women reported experiencing more hot flashes than premenopausal or perimenopausal women. 13, 21 However, neither study included a nonYHIV-infected comparison group. In contrast, studies by Ferreira et al 22 and Miller et al 20 compared the prevalence of menopause symptoms among premenopausal, perimenopausal, and postmenopausal HIV-infected and nonYHIV-infected women. 20, 22 Ferreira et al 22 found that 78% of Brazilian HIV-infected women reported vasomotor symptoms compared with 60% of nonYHIV-infected women, although symptom prevalence was not reported with regard to specific menopause stage and data on symptom intensity were not available. Similarly, Miller et al 20 evaluated the prevalence of menopause symptoms in a cohort specifically designed to recruit premenopausal, perimenopausal, and postmenopausal HIVinfected and drug-using women and found that a greater number of HIV-infected women reported vasomotor symptoms (64% vs 58%). However, although the prevalence of vasomotor symptoms is higher among women with HIV, to our knowledge, no prior study has evaluated whether hot flashes are more severe or have greater negative impact on mood, relationships, social activities, and quality of life in HIV-infected versus nonY HIV-infected women during perimenopause. This information is important because many HIV-infected women are already experiencing an impaired quality of life, and the negative influence of hot flashes may further impact well-being and participation in health-promoting behaviors, including adherence.
This investigation evaluated hot flash severity and interference among perimenopausal HIV-infected and nonYHIVinfected women of similar age, race, and menstrual patterns. We hypothesized that hot flashes would be more severe and would interfere more with daily function in perimenopausal HIV-infected women than in perimenopausal nonYHIV-infected women.
METHODS

Study population and design
Sixty-six women (33 HIV-infected women and 33 nonYHIVinfected women) aged between 45 and 52 years were enrolled at the Massachusetts General Hospital (MGH) from June 2010 to May 2012 for a longitudinal evaluation of menopause symptoms and metabolic changes associated with the menopausal transition. This article reports baseline cross-sectional data on hot flash severity and burden among this cohort. Participants were recruited via advertisements at community acquired immune deficiency syndrome service organizations, newspapers, and outpatient clinics, and through a research participant registry composed of individuals interested in receiving information on clinical trials. Interested participants completed a telephone screen to determine eligibility. Women in both HIV and control groups were required to be clinically perimenopausal (defined as the presence of one menstrual cycle longer than 60 d in the prior 6 mo, or irregular menses in two or more cycles within the past 6 mo). 23 Women were excluded if they had had amenorrhea for 12 months or longer, had had hysterectomy or any active cancer, were pregnant or breast-feeding in the past year, or were using hormone therapy of any kind in the past 6 months. HIVinfected women were on a stable treatment regimen for at least 3 months and were excluded if they had been diagnosed with an opportunistic infection within the 3 months before study enrollment. A stratification algorithm was used in recruitment to ensure that HIV-infected and nonYHIV-infected women were similar. Women were recruited in blocks of 10, starting with HIV-infected women, and were stratified by age, race, and menstrual patterns (having more than or less than six periods in the prior year). Similar numbers in each stratification block were recruited. A written informed consent form was obtained from all participants before enrollment. This study was approved by the Partners Institutional Review Board at the MGH and conducted in accordance with their guidelines for experimental investigation with human participants.
Measurements
Eligible participants were seen at the MGH Clinical Research Center. A comprehensive health history was obtained, including assessment of menstruation history and menstrual patterns; medication use, including selective serotonin reuptake inhibitor (SSRI) use; and HIV-specific health characteristics.
To further characterize the population, we measured serum estradiol and follicle-stimulating hormone (FSH) levels via Access Chemiluminescent Immunoassay (Beckman Coulter, Fullerton, CA). These levels were not obtained on specific days of the menstrual cycle. CD4 cell count was measured via flow cytometry (MultiTEST CD3 FITC/CD8 PE/CD45 PerCP/CD4 APC reagent; Becton Dickinson Biosciences, San Jose, CA).
Questionnaires
Women were asked if they have experienced hot flashes in the past year and reported the number of days they had experienced hot flashes in the past 4 weeks. The Menopause Rating Scale (MRS) was used to assess the presence and severity of menopause symptoms. 24, 25 The MRS is an 11-item questionnaire composed of three symptom domains: somatic symptoms (eg, hot flashes), psychological symptoms (eg, depressive mood), and urogenital symptoms (eg, vaginal dryness). Women were asked to report symptoms and the severity of each symptom (0, none; 1, mild; 2, moderate; 3, severe; 4, extremely severe) experienced at this time. The total MRS score was computed by adding each individual item score (0, asymptomatic; 44, highest degree of complaint). Similar to others, 26<28 item 1 of the MRS was used to assess hot flash severity.
The Hot Flash Related Daily Interference Scale (HFRDIS), a 10-item questionnaire, was completed to determine the impact of hot flashes on daily activities and quality of life. 29 Women rated the degree of hot flash interference (during the past week) for each item on a scale from 0 (does not interfere) to 10 (completely interferes); a higher total score indicates greater interference (score range, 0-100). The total HFRDIS score and individual item scores are presented to demonstrate the degree of interference with each individual's activity and quality of life.
Statistical analysis
Student's t test was used to analyze normally distributed continuous variables, with data presented as mean (SD). Wilcoxon rank sum test was used to analyze nonYnormally distributed variables, with data presented as median (interquartile range). Categorical variables were analyzed using W 2 test and are presented as proportions. Hot flash severity (MRS item 1), overall menopause symptom severity (total MRS score), and hot flash interference (total HFRDIS scores) were compared between HIV-infected and nonYHIV-infected women using linear regression models after adjusting for characteristics that differed between the groups, including smoking and history of substance abuse. Models were further adjusted for hot flash frequency.
With 66 participants, a power of 0.8, and a two-sided 0.05 significance level, the study had power to detect a 0.7-SD difference between the groups. All analyses were performed using SAS JMP statistics software, version 9.0 (SAS Institute Inc, Cary, NC). Statistical significance was assumed if the P value was less than or equal to 0.05.
RESULTS
Study population
A total of 66 women (33 HIV-infected and 33 nonYHIVinfected) were enrolled, and their characteristics are presented in Table 1 . Women were similar in age, race, and menstrual patterns. The median age of both groups was 47 years, and more than half of the women were of diverse racial and ethnic backgrounds. More HIV-infected women than nonYHIV-infected women were current smokers (70% vs 42%, P = 0.03; Table 1) , and a greater number of HIV-infected women than nonYHIVinfected women reported having a history of substance use (76% vs 36%, P = 0.001; Table 1 ). Few women were taking methadone, the prevalence of which did not differ between the groups (Table 1 ). SSRI use was not different between the Table 1 ). Ninety-four percent of HIV-infected women compared with 85% of nonYHIVinfected women reported experiencing hot flashes in the past year (P = 0.23). The median number of days with hot flashes during the 4-week period preceding study entry was 8 days for the cohort overall. The median (interquartile range) number of days in the past 4 weeks during which HIV-infected and nonYHIV-infected women reported experiencing hot flashes was 12 (3-28) and 3 (0-18) days (P = 0.10), respectively, with HIV-infected women being more likely than nonYHIV-infected women to have experienced hot flashes on at least 8 days in the past 4 weeks (67% vs 42%, P = 0.048; Table 1 ). No difference in FSH or estradiol levels was observed between the groups (Table 1) .
Among HIV-infected women, the mean (SD) duration of HIV infection was 14 (6) years (Table 1) . Ninety-one percent of HIV-infected women were receiving ART, and the mean (SD) CD4 cell count was 686 (432) cells/KL (Table 1) . Within the HIV-infected group, hot flash frequency did not correlate with CD4 cell count or duration of HIV.
Hot flash severity and menopause symptoms
HIV-infected women experienced greater hot flash severity compared with nonYHIV-infected women (MRS item 1: 2 [1-3] vs 1 [0-3], P = 0.03; Table 2 ). Specifically, these findings indicate that HIV-infected women were experiencing moderate hot flash severity, compared with mild hot flash severity experienced by nonYHIV-infected women (Table 2) . HIVinfected women also had higher total scores on the MRS (15 [8] vs 10 [7] , P = 0.008), indicating worse menopauserelated symptom severity overall (Table 2) . HIV-infected women reported more sleep problems (MRS item 3: 2 [1-3] vs 2 [0-2], P = 0.04) and psychological symptom severity, including depressed mood, irritability, and anxiety (MRS items 4-6, P e 0.05 for all comparisons; Table 2 ). No significant difference in urogenital symptoms, including sexual problems (MRS item 8, P = 0.25) and vaginal dryness (MRS item10, P = 0.41), was observed between the groups (Table 2) . Within the HIVinfected group, hot flash severity did not correlate with CD4 cell count or duration of HIV.
Hot flashYrelated interference
HIV-infected women in this study also reported greater interference of hot flashes with daily function compared with nonY HIV-infected women, as evidenced by significantly higher total scores on the HFRDIS (37 [10-60] vs 6 [0-20], P = 0.001; Table 3 ). Individual HFRDIS item analyses demonstrated that HIV-infected women experienced a greater degree of hot flash interference with all activities compared with nonYHIV-infected women (HFRDIS items 1-9; Table 3 Differences between HIV-infected and nonYHIV-infected women in total HFRDIS score, total MRS score, and MRS item 1 score remained generally significant after adjusting for differences in smoking status and substance abuse history (Tables 2, 3 ). HIV status also remained significant for total HFRDIS score and total MRS score, after controlling for hot h flash frequency. However, between-group differences for hot flash severity (MRS item 1) were no longer significant after controlling for hot flash frequency (Table 2) .
DISCUSSION
Results of this study show that perimenopausal HIV-infected women experience greater hot flash severity and greater hot flashYrelated interference with daily activities and quality of life compared with well-matched perimenopausal nonYHIVinfected women. Within the HIV-infected group, hot flash frequency, severity, and interference did not correlate with CD4 cell count or duration of HIV. Our findings suggest a greater burden of hot flashes among perimenopausal women who are infected with HIV, which may have important consequences for their quality of life and may potentially reduce their adherence to ART.
Early studies among HIV-infected perimenopausal and postmenopausal women demonstrated an association between HIV-specific characteristics and vasomotor symptoms. An investigation by Clark et al 11 demonstrated that menopausal HIVinfected women with higher CD4 cell counts (9500 cells/KL) were more likely to report hot flashes. Similarly, Miller et al 20 observed a reduction in the prevalence of menopause symptoms as CD4 cell count declined (G200 cells/KL) among HIVinfected non-ART users. Although these studies show that hot flash prevalence correlates with CD4 cell count, we did not observe this pattern for hot flash severity or hot flashYrelated interference in our sample, although few of our participants had a CD4 count below 200 cells/KL. We also did not observe a relationship between hot flash severity or interference and duration of HIV. Possible explanations for greater hot flash severity in the HIV-infected population include the effects of ART or immunological dysfunction on estradiol metabolism or function (although our sample may have been too small to show these associations) or, perhaps, a stronger relationship between HIV-related factors and symptom severity is observed among postmenopausal women, who have endured a longer duration of estrogen suppression.
Smoking and illicit substance use have been shown in prior studies to influence the presence and/or severity of hot flashes among nonYHIV-infected women. 30<32 In a study among premenopausal, perimenopausal, and postmenopausal HIVinfected and nonYHIV-infected drug-using women, a higher prevalence of hot flashes was observed among HIV-infected women. 20 Although the increased smoking rates and substance abuse history commonly seen in HIV-infected women might be thought to contribute to increased hot flash severity, our results were generally unaffected by adjustments for these differences between the groups.
Previous research has demonstrated that HIV-infected women may enter menopause at an earlier age than nonYHIV-infected women 10<13 and therefore may develop hot flashes at an earlier age, raising the possibility that our HIV-infected group reported greater hot flash severity and interference because they had experienced hot flashes for a longer duration. However, the age of our study participants is within the normal age range for perimenopause, and we purposefully matched women in the groups with respect to not only age but also number of menstrual periods in the prior year. Estradiol and FSH levels were not different between the groups, suggesting that the women were at similar stages of the perimenopausal transition with regard to age, menstrual patterns, and biological indices. We also did not observe differences in the use of SSRIs, which have been shown to reduce hot flash severity in nonYHIV-infected women during the menopause transition. Given these findings, further research is necessary to determine the mechanism of increased hot flash severity among HIVinfected perimenopausal women.
In addition to greater hot flash severity, HIV-infected women experienced greater hot flashYrelated interference with sleep, mood, relationships, daily activities, and quality of life compared with nonYHIV-infected women. Although the HFRDIS has not been used previously in HIV-infected women, this instrument has been used in other populations of chronically ill women, such as breast cancer survivors. 34 Similar to our findings, Carpenter et al 34 demonstrated that breast cancer survivors (including those who were naturally postmenopausal) reported more severe hot flashes and greater hot flash interference compared with healthy women. 34 Carpenter et al 34 also reported differences in hot flashYrelated interference with overall quality of life among their cohort, using the HFRDIS quality-of-life item 10. Interestingly, HIV-infected women in our study reported a higher mean score for the overall quality-of-life item, indicating more interference than did breast cancer survivors in the study by Carpenter et al 34 HIV-infected women in this cohort also reported more severe sleep problems (difficulty falling asleep, sleeping through the night, and waking up early), depressive symptoms, irritability, and anxiety compared with nonYHIV-infected women (MRS items 3-6). Consistent with this finding, HIV-infected women experienced greater hot flashYrelated interference with sleep, mood, and concentration (HFRDIS items [4] [5] [6] . Further studies are needed to determine the association of hot flash severity with sleep and mood among a larger group of perimenopausal HIV-infected women, specifically to identify HIVrelated characteristics that may influence this relationship.
This study has limitations. Although the comparison groups are closely matched by demographics and menstrual patterns, there may be residual confounding by factors that were not measured. Perimenopause status was assessed cross-sectionally based on retrospective menstrual cycle patterns reporting rather than prospective monitoring or FSH criteria. In addition, given that this study was designed to recruit perimenopausal women exclusively, study findings may be most relevant to HIV-infected women experiencing perimenopause and not generalizable to postmenopausal women. Recall bias may have influenced menopause symptom occurrence and menstrual patterns, which were retrospectively assessed. However, recall should not have differed between the groups. Based on the findings of the present study, additional studies are needed to further investigate the effects of HIV infection, immune function, and ART class/ specific medications on vasomotor symptoms among a larger cohort of HIV-infected women.
CONCLUSIONS HIV-infected women are living longer, and more are now entering perimenopause. Many HIV-infected individuals are already experiencing a reduced quality of life owing to illnessrelated factors 35 and social stressors. Our data suggest that, for perimenopausal HIV-infected women, hot flashes may be an additional burden on quality of life, which may destabilize an already precarious situation of wellness, abstinence from substances, and adherence to ART. These data highlight the need for clinicians to include a comprehensive review of hot flashes in their assessment of midlife HIV-infected women, as effective treatments that may reduce symptom burden and improve quality of life in this population are available.
